Abstract: A nondestructive inspection method includes steps of: (1) forming a first inspection standard using a metal injection molding process; (2) forming a second inspection standard using the metal injection molding process; and (3) creating a reference library that includes the first and the second inspection standards. The first inspection standard includes a first crack, induced by at least one of a thermal shock and a thermal stress. The second inspection standard includes a second crack, induced by at least one of the thermal shock and the thermal stress. At least one of the thermal shock and the thermal stress introduced during a sintering operation for the first inspection standard is different than at least one of the thermal shock and the thermal stress introduced during the sintering operation for the second inspection standard. The first crack and the second crack are different.

Abstract: A method for inspecting a component made of press-hardening steel prior to resistance spot welding of the component includes performing non-destructive testing of the component made of press-hardening steel after hot stamping to determine a plurality of characteristics for the component. The non-destructive testing comprises at least one of image processing, electromagnetic analysis, and elemental analysis of the component. The method includes using a model correlating values of the characteristics to acceptable weld quality or rejected weld quality and predicting acceptable weld quality or rejected weld quality of the component prior to resistance spot welding of the component; resistance spot welding the component if the model predicts acceptable weld quality; and not resistance spot welding the component if the model predicts rejected weld quality.

Abstract: A heating and cooling device includes a conductive structure, an electric heating pipe and a housing. The housing has a main body and a test space formed in the main body, the electric heating pipe is attached on the main body and used for heating a testing plastic material in the test space, and the housing is covered outside the conductive structure and separated from the main body to form a cooling flow channel. The housing and the main body are separated without contacting each other, so that the dissipation of the heat energy of the electric heating pipe through the housing can be reduced in the heating process, and the function of thermal preservation can be provided. Moreover, the cooling effect can be improved through the larger cooling flow channel during the cooling process. A PVT equipment using the heating and cooling device is further provided.

Abstract: The present invention relates a porous membrane sensor element for the detection of an analyte in a complex fluid sample.

Abstract: An object of the present technology is to provide a sample preparation system for increasing a content ratio of target cells. The present technology provides a sample preparation device including a container, and a channel in which a bioparticle-containing liquid flows, the channel accommodated in the container, in which the channel is formed such that a centrifugal force acts on the bioparticle-containing liquid, and an outer peripheral wall of the channel is formed such that at least part of components of the bioparticle-containing liquid may be transferred to an outside of the channel. Furthermore, the present technology also provides a sample preparation system including the sample preparation device, and an analysis device that executes analysis of the bioparticle-containing liquid that passes through the channel.

Abstract: Provided are systems and methods for analyte detection and analysis. A system can comprise an open substrate configured to rotate. The open substrate can comprise an array of immobilized analytes. A solution comprising a plurality of probes may be directed, via centrifugal force, across the array during rotation of the substrate, to couple at least one of the plurality of probes with at least one of the analytes to form a bound probe. A detector can be configured to detect a signal from the bound probe via continuous rotational area scanning of the substrate.

Abstract: A method of remote control of the alcohol content in the exhaled air is described. The alcohol concentration in the exhaled air is measured by means of a control device with a radio data transmission ability. The created set reference data including identifiers of the device and the user is stored in a web application data collection module on a server contained inside the network data analysis infrastructure. It is then used to train the deep model a convolutional neural network whose task is to classify and identify the characteristic visual features of the individual faces of users, individual features identifying the control device. This information being compared with the value of the alcohol concentration in the exhaled air obtained from the control device with the date, time, geographical location to verify alcohol readings and to take actions such as preventing access to a workplace.

Abstract: The present invention provides methods for using waste effluent biofluids in cell culture assays as all or part of the cell culture microenvironment. Methods of the invention contemplate that biofluids typically regarded as waste may be used in cell-based assays to achieve a cell culture microenvironment that provides a novel understanding of cellular response.

Abstract: The present invention discloses a method for building a co-culture model for Caco-2/RAW-264.7 cells induced by lipopolysaccharides and an application of the co-culture model. The method includes: 1) culturing Caco-2 cells and RAW-264.7 cells; 2) inoculating the 5 Caco-2 cells onto an AP side of an upper chamber of a Transwell plate, and incubating; 3) inoculating the RAW-264.7 cells onto a 24-well plate, and incubating; 4) transferring the upper chamber of the Transwell plate into the 24-well plate; 5) dissolving lipopolysaccharides in PBS to prepare a stock solution, filtering, and diluting for later use; and 6) adding an LPS-10% DMEM medium on a BL side, incubating, and forming an intestinal inflammation model.

Abstract: Food allergens and environmental allergens are more readily assessed in vitro than with cumbersome and variable skin tests. Methods for measuring basophil response to allergens are improved when a variety of time points are interrogated and rates of change considered. Interrogation of internal and external markers of basophil activation also improves assessments.

Abstract: The disclosure provides a method for identifying a bio-entity including a cell type and count in a sample. The method includes: providing a device comprising a first plate, a second plate, and a patterned structural element; depositing the sample between the first and second plates; reducing the spacing of the first and second plates so that the first and second plates are in a closed configuration to compress the sample into a layer; and imaging the sample to obtain an image; and measuring and analyzing the image against a database generated with a machine learning model to obtain the bio-entity of the sample. The sample can be a blood sample, and the method can be a white blood cell differential test conducted with a mobile phone.

Abstract: The present disclosure shows that inflammation in metabolic syndrome is augmented by and hitherto overlooked lock-and-key activation of the elastin receptor, a protein involved in vascular (blood vessel) inflammation and elastin repair, with the C-peptide, a small protein that is produced in a 1:1 ratio alongside with widely known insulin. The elastin receptor is the lock that is activated by a key motif of amino acids (PG-domain) found in C-peptide and in breakdown products (PG-domain-fragments) thereof. Until now, no one has ever discovered this lock-and-key interaction between the two, now providing novel development of novel peptides for treatment of metabolic syndrome, exploiting the finding that not only the normal keys of the elastin receptor (elastin peptides), but also the C-peptide, a peptide we produce together with insulin every time glucose rises in our blood after a meal, interacts in a lock-and-key mode with the elastin receptor.

Abstract: The inventions provide immunoassays for reducing the effects of interference in the detection and quantification of analytes, including but not limited to cytokines, enzymes, antibodies, and others by acidifying samples and allowing for binding of the analytes and corresponding capture reagents in the acidified samples without neutralization.

Abstract: Provided herein are structures and methods for detecting one or more analyte molecules present in a sample. In some embodiments, the one or more analyte molecules are detected using one or more supramolecular structures. In some embodiments, the one or more supramolecular structures are specifically designed to minimize cross-reactivity with each other. In some embodiments, the supramolecular structures are bi-stable, wherein the supramolecular structures shift from an unstable state to a stable state through interaction with one or more analyte molecules from the sample. In some embodiments, the stable state supramolecular structures are configured to provide a signal for analyte molecule detection and quantification. In some embodiments, the signal correlates to a DNA signal, such that detection and quantification of an analyte molecule comprises converting the presence of the analyte molecule into a DNA signal.

Abstract: The present disclosure relates to methods for characterizing formulations comprising aluminum hydroxide particles (alum), an antigen bound to the alum, and an unmethylated cytidine-phospho-guanosine-containing oligodeoxynucleotide (CpG ODN). In particular, the present disclosure provides methods for determining concentration of CpG ODN in a vaccine formulation through use of a colorimetric assay for measuring total phosphorus.

Abstract: Methods which use click-chemistry modified monosaccharide compounds of the pentose phosphate pathway, e.g. ribose, ribulose, arabinitol, xylulose, xylose or xylitol, for labeling and/or detecting an eukaryotic cell from a multicellular organism. It also relates to such modified monosaccharide compounds implemented in methods for identifying or isolating cancer cells, diagnosing a cancer or for cell therapy.

Abstract: The present technology relates to cell-free systems, methods, and kits for expressing proteins in vitro and evaluating the expressed proteins. In particular, the technology relates to cell-free systems, methods, and kits for expressing antibodies, antigen-binding fragment thereof, and antibody derivatives in vitro and evaluating the expressed antibodies, antigen-binding fragment thereof, and antibody derivatives.

Abstract: Droplet-interface bilayer and lipid bilayer membrane compositions stabilized with an amphiphilic polymer are disclosed. Methods of making and using the compositions are also disclosed.

Abstract: Disclosed herein are immunoassays for detecting an anti-thyroid peroxidase antibody in a biological sample from a subject and/or diagnosing a thyroid disease in a subject. The disclosed immunoassays employ a recombinant cynomolgus monkey thyroid peroxidase (rTPO) and assess the level of anti-thyroid peroxidase antibody-induced formation or disruption of complexes comprising a solid support and the rTPO.

Abstract: A method of making a plasmon-resonance biosensor includes conjugating precious metal nanorods with form factor at least 1.5 with a biological probe material. Microfluidic chambers of volume under 0.025 microliter are formed over a substrate, and an aqueous suspension of the conjugated nanorods is injected into the chambers. The nanorods are organized in rows and aligned in long dimension along the rows. The biosensor is configured to be read by obtaining an optical absorption spectrum upon exposure to the analyte. The biosensor includes precious metal nanorods organized in rows with long dimension approximately parallel to the rows. The nanorods are conjugated with biological probes capable of binding to an analyte, the probes may be an aptamer, an antibody, a protein-nucleic acid (PNA), a complimentary DNA, or an enzyme having a binding site.

Abstract: An assay cartridge is an assay cartridge that is attachably and detachably loaded into an immunochromatographic assay apparatus, including a carrier having an assay region in which a color development state changes depending on whether a sample is positive or negative, a case in which the carrier is accommodated, and an opening portion that is provided in the case, is used for observing an observation region LA including the assay region, and is illuminated by a light source in the immunochromatographic assay apparatus, in which at least a part of an inner peripheral wall 18A of the opening portion is a processed surface having an angle of 50° or more with respect to a surface of the observation region LA and having been subjected to a roughening treatment.

Abstract: The present disclosure relates to a lateral flow test device for performing a lateral flow test on a liquid sample, comprising: a test strip which comprises: a nitrocellulose membrane having a first capturing reagent disposed on a first surface along a test line, the first capturing reagent being configured to capture a first analyte in the liquid sample; a sample pad disposed at a first end of the nitrocellulose membrane configured to receive the liquid sample; a labelling reagent comprising a plurality of label molecules disposed on the first surface at a position between the sample pad and the test line, the label molecules being configured to bind to the first analyte; and an electrode array disposed over the nitrocellulose membrane configured to apply an electric potential across the first surface.

Abstract: This invention relates to a specimen-extracting solution containing a component capable of strongly suppressing false negatives, which could not be suppressed by conventional techniques, a method for extracting specimens, and a test reagent using such specimen-extracting solution and such method, when detecting virus, bacteria, target protein, or other antigens from specimens derived from body fluids, such as nasal swab specimens, nasal aspirate specimens, nasal wash specimens, nasal secretion specimens collected by nose blowing, pharyngeal swab specimens, saliva specimens, fecal specimens, serum specimens, plasma specimens, and urine specimens, with the use of a detection reagent utilizing the antigen-antibody reactions or the reactions between substances interactive with each other.

Abstract: A particle including a polymer which has a repeating unit derived from a vinyl-based monomer. The particle has a specific structure containing a carboxy group, and a surface of the particle contains a water-soluble polymer.

Abstract: A method for predicting an immunogenic and/or therapeutic response to adalimumab 5 from a sample extracted from a rheumatoid arthritis patient by testing the sample for the presence of biomarkers, the biomarkers being autoantibodies to antigens comprising SSB, TROVE2 and ZHX2.

Abstract: Disclosed are methods and systems for the isolation and detection of microbes from a sample. The use of binding agents for isolation of a microbe of interest from a sample are described. In certain embodiments, the methods use ribosome-based and/or bacteriophage-based amplification of the signal in detection of bacteria and other microorganisms. For example, embodiments of the present invention can achieve total amplification of at least 10,000 from a single infected cell.

Abstract: The present invention provides methods for the identification, isolation and/or enrichment of human corneal endothelial cells (HCECs). In some embodiments, the method comprises a positive selection process in which a cell population containing human corneal cells is contacted with a positive affinity reagent that selectively binds to HCECs relative to cells other than HCECs (e.g., corneal keratocytes, etc.) in the population and/or a negative selection process in which a cell population containing HCECs is contacted with a negative affinity reagent that selectively binds to cells other than HCECs in the population relative to HCECs. The present invention also provides reagents and kits for the identification, isolation and/or enrichment of HCECs as well as compositions that are enriched in HCECs.

Abstract: In one embodiment, a method of building an optimized color flow cytometry panel is disclosed using a spectral flow cytometer with a least three excitation lasers and thirty-eight color detectors. In another embodiment, a graphical user interface is disclosed generated by a server computer from a fluorochrome database and displayed by a client computer to assist in the selection of a set of fluorochromes for use in an assay to analyze biological samples. The GUI can display spectra graphs to visually show how fluorochromes may overlap and can generate similarity indexes for the paired fluorochrome interference and a complexity index for overall many to many interferences generated by a selected group or set of fluorochromes.

Abstract: In one embodiment, a method of building an optimized color flow cytometry panel is disclosed using a full spectrum flow cytometer with five excitation lasers and five corresponding detection modules. In another embodiment, a graphical user interface is disclosed generated by a server computer from a fluorochrome database and displayed by a client computer to assist in the selection of a set of fluorochromes for use in an assay to analyze biological samples. The GUI can display spectra graphs to visually show how fluorochromes may overlap and can generate similarity indexes for the paired fluorochrome interference and a complexity index for overall many to many interferences generated by a selected group or set of fluorochromes.

Abstract: The present invention provides an improvement method and a system for decreasing the limit of detection of the presence of an analyte in a sample. In particular, the present invention provides an article or a system, such as a diagnostic kit, for detecting the presence of an analyte in a sample, comprising (i) a microsphere coated with an affinity ligand, or a spore or bacterium expressing one or more proteins on the surface thereof, (ii) a signal-producing substances, and (iii) a binding agent, wherein the signal-producing substance is conjugated with the binding agent and an antibody specific to the affinity ligand on the microsphere or the protein expressed by the spore or bacterium, wherein the signal-producing substances are conjugated to the microsphere, spore or bacterium through the binding of the antibodies specific to the affinity ligand or the protein.

Abstract: Compositions and methods are provided for detection, diagnosis and prognosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) and for characterization of SARS-CoV-2 antigen-specific T-cell immune responsiveness in COVID-19 patient samples, including in secondary in vitro immune response assays for long-lived anamnestic (memory) T-cell responses. Disclosed compositions and methods include a method that comprises contacting, in vitro, whole blood samples from subjects suspected of having COVID-19 or who have previously been exposed to SARS-CoV-2, with synthetic peptides comprising T-cell epitope-containing regions derived from SARS-CoV-2 Spike proteins; and indirectly detecting SARS-CoV-2-specific activated T-cells by determining production of a T-cell immune response indicator (e.g., interferon-?) in response to stimulation by the Spike protein-derived peptides.

Abstract: The present invention relates to biomarker sensors with a multielectrode array structure, kits containing them, methods for their production as well as corresponding uses and applications.

Abstract: Disclosed are methods, systems and devices for detection of biomarkers. In certain embodiments, the methods and/or devices and/or systems may be used for the detection of biomarkers characteristic of disease. For example, disclosed are methods, systems and devices that may be used to detect and distinguish a biomarker profile indicative of the presence of COVID-19 as either an active infection, or a subject in remission, or a subject who has not been exposed to the virus.

Abstract: Described are systems and assays that monitor presence and/or quantity of herpesviruses viral proteins. Embodiments offer accurate detection and quantification of viral proteins from all temporal classes of viral replication. Three exemplary assays provide specific detection of: herpes simplex vims type 1 (HSV1), human cytomegalovirus (HCMV), and Kaposi's sarcoma-associated herpesvirus (KSHV). These assays can be utilized in combination with drug treatments, genetic modifications, or other perturbations to assess the impact of the intervention on viral protein production.

Abstract: The disclosed technology relates to chemical entities for the detection of wounds, e.g., chronic wounds or infected wounds, including compositions, substrates, kits, dressing materials, and articles, and systems containing such compounds. The disclosed technology further relates to methods of using these compositions, kits and systems in diagnostic assays, and in the diagnosis and/or detection of chronic or infected wounds based on enzymatic action on specific moieties and/or reaction sites. The disclosed technology additionally relates to detection of pathogenic, e.g., bacterial and/or viral substances, such as enzymes and substrates, at the wound situs. Additional disclosure relates to methods of characterizing wounds based on expression of a plurality of markers and using such information to treat, manage, and follow-up patients suffering from chronic or infected wounds.

Abstract: Provided is a method of assisting breast cancer diagnosis, comprising: a measuring step for measuring an amount of laminin 5 or laminin ?3 in a specimen; and an information-providing step for providing information for breast cancer diagnosis based on the amount of laminin 5 or laminin ?3 thus measured. Provided is a test kit for breast cancer comprising an anti-laminin 5 antibody or an anti-laminin ?3 antibody.

Abstract: The present invention relates to methods of diagnosing lung cancer in a patient, as well as methods of monitoring the progression of lung cancer and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.

Abstract: In one embodiment, a method of building an optimized color flow high parameter reagent and reagent kit cytometry panel for detection of aberrant cells in acute myeloid leukemia is disclosed using a spectral flow cytometer with a least three excitation lasers and thirty-eight color detectors. In another embodiment, a graphical user interface is disclosed generated by a server computer from a fluorochrome database and displayed by a client computer to assist in the selection of a set of fluorochromes for use in an assay to analyze biological samples. The GUI can display spectra graphs to visually show how fluorochromes may overlap and can generate similarity indexes for the paired fluorochrome interference and a complexity index for overall many to many interferences generated by a selected group or set of fluorochromes.

Abstract: The present invention provides methods for predicting response to a hormone-directed therapy or chemotherapy in a prostate cancer (PCa) patient comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characteristization of nucleated cells in a blood sample obtained from the patient to identify and enumerate circulating tumor cells (CTC); (b) individually characterizing genotypic, morphometric and protein expression parameters to generate a profile for each of the CTCs, and (c) predicting response to hormone-directed therapy in the prostate cancer PCa patient based on said profile. In some embodiments, the methods comprise repeating steps (a) through (c) at one or more timepoints after initial diagnosis of prostate cancer to sequentially monitor said genotypic, morphometric and protein expression parameters.

Abstract: The invention relates to in vitro methods for predicting tumour progression or response to anticancer therapy of a cancer patient the method comprising the steps of: 1) providing engineered mammalian immune cells comprising: —a NFkB signalling reporter construct and an IFN signalling reporter construct, 2) contacting the engineered cells with a blood sample of a cancer patient, allowing induction of the NFkB and/or IFN signalling pathways of said engineered cells by the blood sample, 3) determining the expression and/or activity levels of the first and second reporter protein, 4) comparing the expression levels and/or activity of the first and second reporter protein determined in step 3) with the expression and/or activity levels of the first and second reporter protein in a reference sample of a healthy individual, 5) based on the comparison predicting tumour progression, or response to anticancer therapy of the cancer patient.

Abstract: The present disclosure relates to biomarker profiles and their use to predict a subject's response to an immunomodulatory treatment. Biomarkers in these profiles include cytokines and other proteins associated with the interleukin 1 family and the type 1 interferon family. Particular biomarkers include interleukin (IL)-2, soluble IL-2 receptor alpha (sIL-2RA), IL-5, IL-6, IL-9, IL-10, IL-18, IL-18 binding protein (IL-18BP), IL-18 receptor 1 (IL-18R1), IL-18 receptor accessory protein (IL-18RAP), IL-22, C-type lectin-like receptor (CD161), CD56, interferon gamma (IFN?), granulocyte macrophage colony stimulating factor (GM-CSF), serum amyloid A (SAA), and C-reactive protein (CRP). Particular biomarkers also include populations of cells including CD161+ cells and CD56+dim cells. The biomarker profiles can be used to predict a subject's responsiveness to an immunomodulatory treatment (e.g.

Abstract: The invention provides a method, device, kit and computer-implemented method for diagnosing (and optionally also treating) cancer. The method for diagnosing cancer comprises the step of testing a blood sample from a subject suspected of having cancer for the presence of Ipo5 (Importin 5) and at least one other biomarker, the at least one other biomarker being selected from Ran (Ras-related nuclear protein) and KpnB1 (Karyopherin beta 1). The blood sample may also be tested for additional biomarkers such as CRM1 (Cross-Reactive-Material-197), Kpna2 (Karyopherin alpha 2), CAS (Cellular apoptosis-susceptibility protein) and Transportin 1.

Abstract: The invention relates to array-based methods for identification of neoepitope reactive T cells and to compositions produced using such methods. Aspects of the invention relate to rapid and reliable methods to identify neoepitope reactive T cells.

Abstract: The invention provides anti-human pro-epiregulin and anti-human amphiregulin antibodies and methods of using the same. Anti-EREG antibodies raised against amino acids 148-169 and 156-169 of the human EREG protein, and anti-AREG antibodies raised against amino acids 238-252 of the human AREG protein are disclosed. Methods of using these antibodies to detect EREG and AREG and kits and other products for performing such methods are also disclosed.

Abstract: The present application discloses a method of identifying and characterising intact pathogens in a sample using a fluorescence imaging system, in particular for characterising bacteria and viruses, and associated systems and kits for implementing the imethod. The method involves incubating a sample with fluorescent probes from at least two of the following categories: a fluorescent probe for binding to a pathogen surface carbohydrate; a nucleic acid stain; and a membrane stain. The sample is then imaged using fluorescence imaging apparatus to detect candidate objects, and the fluorescence characteristics of the candidate objects used to identify whether the object is a pathogen and, if so, the type of pathogen. Particularly preferred implementations employ flow to improve data acquisition, and machine learning classification algorithms to distinguish different pathogen types.

Abstract: A method of treating a condition in a subject by improving the immune response of the subject comprising first determining the level of TCF1 in the subject to identify the subject as having an anti-PD-1 responder phenotype or an anti-PD-1 non-responder phenotype, then administering an anti-PD-1 treatment to a subject having an anti-PD-1 responder phenotype or a metabolic inhibitor prior to ant-PD-1 treatment to a subject having an anti-PD-1 non-responder phenotype.

Abstract: A method of isolating desmosine and isodesmosine in elastin includes hydrolyzing a sample of elastin and separating the desmosine and isodesmosine within a high-performance liquid chromatography (HPLC) column. A mobile phase gradient includes a first solvent solution of MSA (methane sulfonic acid) and HSA (sodium hexanesulfonate) and a second solvent solution of formic acid in Acetonitrile. The desmosine and isodesmosine may be measured as eluents based upon a HPLC chromatogram.

Abstract: The present invention relates to the field of affinity purification and provides for means and methods applying protein binding agents competing for a target protein for use as capture and elution tool, wherein the elution agent comprises an immunoglobulin single variable domain (ISVD), and is capable of displacing the capturing binding agent. More specifically, the displacement efficiency of the ISVD-containing protein binding agent is driven by its dissociation kinetics, with a rate constant of dissociation (koff) equal or lower as compared to the capturing agent. Furthermore, said protein binding agents are deployable in high-throughput purification from complex mixtures, or for capturing protein-complexes, thereby facilitating structural, biochemical and physicochemical analysis of said target proteins.

Abstract: The present disclosure relates to methods, compositions, systems, and kits for detecting and analyzing the glycosylation of healthy and diseased cells and protein-specific glycosylation patterns using single-cell profiling methodologies.

Abstract: Provided herein are biological vesicles displaying cell surface proteins, as well as methods of using such vesicles to identify and characterize protein-protein interactions.